-
The agreement includes a license agreement for Triple Hair’s patented products in the US
-
Pharmacy Solutions specializes in over-the-counter hair loss medicines, providing unparalleled tailor-made compounding solutions for over 30 years
-
Pharmacy Solutions is licensed in 47 states and has pending licenses in the remaining 3 states
MONTREAL, June 21, 2022 (GLOBE NEWSWIRE) — Triple Hair Group Inc. †Triple Hair” or the “Company”), a company specializing in the development of innovative treatments for alopecia, is pleased to announce that it has entered into a strategic licensing agreement with Pharmacy Solutions to formulate Triple Hair’s hair growth products in the United States. Alopecia is an underserved global market worth $7.8 billion in 2021, an estimated $14.2 billion in 2028.
“This really changes the game for Triple Hair to have Pharmacy Solutions as a strategic partner to develop and sell our hair growth products in the US,” said Jean-Philippe Gravel, President and CEO of Triple Hair. “This agreement has several advantages. It allows us to offer our patented triple combination hair growth product and our two over-the-counter brands, RIZN and Plenty Natural, to people with hair loss in the US. Pharmacy Solutions is a leader in the compounding and supply of pharmaceutical products.”
“We are very pleased to partner with Triple Hair, whose hair growth products are a perfect fit with our business model and expertise,” said Kim Siegenthaler, Director of Business Development at Pharmacy Solutions. “They help fill a critical need and address a very large potential market. We are excited to enter into this partnership with Triple Hair and the opportunity to offer its products within the US.”
The patented triple combination hair growth product is the first product of its kind to combine 3 proven ingredients for the treatment of androgenic alopecia on the market.
About Triple Hair
Triple Hair Group Inc. is a Canadian biotechnology company specializing in developing innovative treatments for men and women suffering from alopecia. Its mission is to provide the underserved market with clinically proven and effective prescription and over-the-counter hair growth treatments.
Triple Hair’s patented Triple Combination Hair Growth Therapy (therapy-07 prescription drug) is known as the most promising and the first product of its kind for the treatment of androgenic alopecia. This clinical stage therapy is made from an optimal fixed dose combination of 3 safe and approved ingredients, proven to be effective in inducing new hair growth in various stages of androgenic alopecia.
The company also markets its drug-free proprietary products for preventing hair loss and regaining hair density in mild to moderate cases of alopecia under the brand names RIZNTM (www.rizn.ca) for men, and Plenty NaturalTM (www.plentynatural.ca) for women. RIZNTM and a lot of courseTM allows people who suffer from early stage hair loss to easily access effective and natural hair growth solutions without a prescription.
For more information, visit the company’s website at www.triplehair.ca.
Forward-Looking Statements
Information and statements provided in this press release that are not purely historical are forward-looking statements within the meaning of applicable securities laws. Certain statements in this press release, such as the competitive advantages of the company’s products, may constitute forward-looking information within the meaning of securities laws. Forward-looking information may relate to the future prospects and expected events, business, operations, financial performance, financial condition or results of the company and may in some cases be identified by terminology such as “may”; “shall”; “should”; “to expect”; “plan”; “anticipate”; “to believe”; “planning on”; “estimation”; “to predict”; “potential”; “Get on”; “provide”, “insure” or other similar expressions in reference to matters that are not historical facts. In particular, statements regarding the future operating results and economic performance of the company and its objectives and strategies are forward-looking statements. These statements are based on certain factors and assumptions, many of which are beyond the company’s control. Although management considers these assumptions reasonable based on the information currently available to the Company, they may prove incorrect. Forward-looking information is also subject to certain factors, including risks and uncertainties that could cause actual results to differ materially from what the company currently expects. Therefore, future events and results could differ materially from what management currently foresees. The reader should not place undue importance on forward-looking information and should not rely on such information as of another date. The Company will not update these statements unless required by applicable securities laws.
Contact:
Triple hair group
Jean-Philippe Gravel
President and CEO
investors@triplehair.ca
